Primary and secondary nonresponse to infliximab: mechanisms and countermeasures
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Primary and secondary nonresponse to infliximab: mechanisms and countermeasures
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 13, Issue 10, Pages 1039-1046
Publisher
Informa UK Limited
Online
2017-09-06
DOI
10.1080/17425255.2017.1377180
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Proactive Monitoring of Infliximab (IFX) and Adalimumab (ADA) Drug and Anti-Drug Antibody Concentration Utilizing the Labcorp Assay in Inflammatory Bowel Disease (IBD) Patients
- (2017) Rajiv A. Perinbasekar et al. GASTROENTEROLOGY
- American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
- (2017) Joseph D. Feuerstein et al. GASTROENTEROLOGY
- Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease
- (2017) Sine Buhl et al. INFLAMMATORY BOWEL DISEASES
- Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis
- (2017) Dean Seah et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience
- (2016) T. Billiet et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis
- (2016) B. Ungar et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2016) Bella Ungar et al. Clinical Gastroenterology and Hepatology
- Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
- (2016) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- Standardisation of Study Protocols – Pros and Cons
- (2016) Geert D’Haens Journal of Crohns & Colitis
- Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab
- (2016) Konstantinos Papamichael et al. Journal of Crohns & Colitis
- Loss of Response to Anti-TNFs: Definition, Epidemiology and Management
- (2016) Giulia Roda et al. Clinical and Translational Gastroenterology
- Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
- (2015) Henit Yanai et al. Clinical Gastroenterology and Hepatology
- An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
- (2015) David J. Gibson et al. Clinical Gastroenterology and Hepatology
- Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn’s Disease: Avoiding Failure While Lowering Costs?
- (2015) Niels Vande Casteele et al. DIGESTIVE DISEASES AND SCIENCES
- Ulcerative Colitis Care Pathway
- (2015) Themistocles Dassopoulos et al. GASTROENTEROLOGY
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
- (2015) Johannan F. Brandse et al. GASTROENTEROLOGY
- 1071 Development and Validation of a Novel Enterography-Based Stricture Severity Score (SSS) to Predict the Need for Surgery in Patients With Stricturing Crohn's Disease
- (2015) Sansrita Nepal et al. GASTROENTEROLOGY
- Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
- (2014) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Crohn’s Disease Evaluation and Treatment: Clinical Decision Tool
- (2014) William J. Sandborn GASTROENTEROLOGY
- Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease
- (2014) Byron P. Vaughn et al. INFLAMMATORY BOWEL DISEASES
- Optimizing anti-TNF treatments in inflammatory bowel disease
- (2013) Shomron Ben-Horin et al. AUTOIMMUNITY REVIEWS
- A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
- (2013) Fernando S. Velayos et al. Clinical Gastroenterology and Hepatology
- Does Anti-TNF Therapy Cost So Many COINs?
- (2013) Xavier Roblin et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
- (2012) Shomron Ben–Horin et al. Clinical Gastroenterology and Hepatology
- Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
- (2012) I Ordás et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
- (2011) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Computed tomography enterography findings correlate with tissue inflammation, not fibrosis in resected small bowel Crohnʼs disease
- (2011) Jeremy Adler et al. INFLAMMATORY BOWEL DISEASES
- Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience
- (2011) Michael B. Sprakes et al. Journal of Crohns & Colitis
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
- (2010) Matthieu Allez et al. Journal of Crohns & Colitis
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
- (2009) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis
- (2009) Trine Olsen et al. CYTOKINE
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
- (2009) Adedigbo A. Fasanmade et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
- (2009) C H Seow et al. GUT
- Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
- (2008) Laurent Peyrin–Biroulet et al. Clinical Gastroenterology and Hepatology
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More